Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, Randomized Study

Transplantation

Volumn 99, Issue 10, 2015, Pages 2158-2166

  Størset, Elisabet ^a,b   Åsberg, Anders ^a,b   Skauby, Morten ^a   Neely, Michael ^c   Bergan, Stein ^b,d   Bremer, Sara ^d   Midtvedt, Karsten ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG TARGETING; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; COMPUTER SIMULATION; GENOTYPE; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RENAL INSUFFICIENCY; RISK FACTOR; SOFTWARE; THEORETICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMPUTER SIMULATION; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; SOFTWARE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84943146508     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000708     Document Type: Article

References (47)

1. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant. 2014;14(Suppl 1):11-44.
2. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004; 43:623-653.
4. Saint-Marcoux F, Woillard J-B, Jurado C, et al. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit. 2013;35:322-327.
5. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905-1909.
6. Richards KR, Hager D, Muth B, et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. Transplantation. 2014;97:986-991.
7. Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit. 2009;31:436-442.
8. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;62:900-905.
9. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
10. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763.
11. Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85:1404-1411.
12. Woillard JB, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71: 391-402.
13. Størset E, Holford N, Midtvedt K, et al. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2013; 70:65-77.
14. Bergmann TK, Hennig S, Barraclough KA, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: Impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36:62-70.
15. Størset E, Holford N, Hennig S, et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014;78:509.
16. van Duijnhoven EM, Boots JMM, Christiaans MHL, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003; 16:721-725.
17. Boots JMM, van Duijnhoven EM, Christiaans MHL, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221-227.
18. Ekberg H, Mamelok RD, Pearson TC, et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation. 2009;87:1360-1366.
19. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87: 721-726.
20. Fuchs A, Csajka C, Thoma Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52:9-22.
21. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294-305.
22. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34:57-77.
23. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
24. Bleyzac N, Souillet G, Magron P et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.
25. Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents. 2002;20:326.
26. Åsberg A, Falck P Undset LH, et al. Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study. Ther Drug Monit. 2010;32:152.
27. Fukudo M, Yano I, Shinsako K, et al. Prospective evaluation of the Bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. J Clin Pharmacol. 2009;49:789-797.
28. Åsberg A, Midtvedt K, van Guilder M, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int. 2013;26:1198-1027.
29. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357: 2562-2575.
30. Wallemacq P Goffinet J-S, O'Morchoe S, et al. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit. 2009;31:198-204.
31. Laboratory of Applied Pharmacokinetics (2014). BestDose. Available at: http://www.lapk.org/bestdose.php. Accessed December 1 2014.
32. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051-1065.
33. Hope WW, Van Guilder M, Donnelly JP, et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother. 2013;57:1888-1894.
34. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/. Accessed December 1 2014.
35. Mallon DH, Summers DM, Bradley JA, et al. Defining delayed graft function after renal transplantation. Transplantation. 2013;96:885-889.
36. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506.
37. Cotovio P, Neves M, Rodrigues L, et al. New-onset diabetes after transplantation: Assessment of risk factors and clinical outcomes. Transplant Proc. 2013;45:1079-1083.
38. Legendre C, Canaud G, Martinez F. Factors influencing long-term outcome after kidney transplantation. Transpl Int. 2013;27:19-27.
39. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonad-herence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769-776.
40. Tielen M, van Exel J, Laging M, et al. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant. 2014;2014:675301.
41. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther Drug Monit. 2010;32:708-714.
42. Neely MN, van Guilder MG, Yamada WM, et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467-476.
43. Jusko WJ, D'Ambrosio R. Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc. 1991;23:2732-2735.
44. Hebert MF, Zheng S, Hays K, et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation. 2013;95:908-915.
45. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials. Am J Transplant. 2013;13:1253.
46. Helal I, Chan L. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Transplant Proc. 2011;43:472-477.
47. Langer RM, Hené R, Vítko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592-602.